GlobeNewswire

Compuware Acquires XaTester and Partners with Parasoft to Deliver Essential Automated Unit Testing to Mainframe DevOps Teams

Dela

https://editorial.globenewswire.com/ResourceLibrary/ResourceLibrary/GetDynamicThumbnailContentContent/?resourceId=63b6178d-f04f-4003-9f2a-fca7ad9a8f2e&maxHeight=150&maxWidth=150

Topaz Further Established as the Leading Solution for Continuously Improving Velocity, Quality and Efficiency of Enterprise Systems

  • Large enterprises must rigorously safeguard the quality of their mission-critical mainframe systems as digital demands drive them to develop and deploy mainframe code more quickly and frequently. 
  • With the acquisition of XaTester, new enhancements, and partnership with Parasoft, Compuware Topaz for Total Test is the clear leader in the automated unit testing essential for Agile and DevOps on the mainframe.
  • With Topaz, developers at all skill levels can quickly and efficiently produce the highest-quality code for the mainframe-enabling enterprises to achieve the digital agility essential for success in fast-moving markets.             

DETROIT, July 18, 2018 (GLOBE NEWSWIRE) -- Compuware today announced a product acquisition, enhancements to Topaz for Total Test, and a partnership that together dramatically improve the ability of large enterprises to embrace Agile and DevOps on their mainframes through the broader use of simplified, automated unit testing-which is essential for fast, safe and efficient development and deployment of new digital deliverables.

To deliver on its vision of Topaz for Total Test as the de facto standard for automating mainframe unit testing across all major mainframe environments and programming languages, Compuware has:

  • Acquired XaTester from Xact Consulting A/S, enabling developers to quickly create unit tests for both batch and CICS-based programs written in COBOL, PL/I and Assembler. CICS is especially important as the transaction processing technology of choice for many of the world's largest enterprises-especially financial institutions and insurance companies-due to its extremely high integrity, performance and scalability.
     
  • Enhanced Topaz for Total Test to provide automated unit testing for IMS batch and transactional applications. Testing for IMS is especially important given that contemporary developers often have little or no hands-on experience with IMS code. These enhancements complement Topaz for Total Test's existing support for batch applications written in COBOL-as well as its integration with leading cross-platform DevOps tools such as Jenkins, SonarSource SonarQube and Compuware ISPW.
     
  • Partnered with Parasoft, a leading innovator in end-to-end test automation for software development. The first deliverable for the partnership is integration between Parasoft SOAtest and Topaz for Total Test. This integration enables developers working on mainframe applications to quickly and easily test API calls between mainframe and non-mainframe systems.

Topaz for Total Test fundamentally transforms mainframe development by giving developers the same type of unit testing capabilities on the mainframe they've become accustomed to on other platforms. Unit testing is a fundamental requirement for modern software development. It enables developers to find potential problems in their code as early as possible, to more quickly and frequently deliver incremental changes in software functionality, and to more granularly document code for the benefit of other developers.

The result for large enterprises is a unified DevOps toolchain that accelerates development across all platforms-including the mainframe-so they can more effectively compete in today's rapidly-changing markets.

"XaTester and Topaz for Total Test are two great and complementary products for automating mainframe unit testing, which is essential to DevOps," said Steen Brahe, Senior Product Manager, Compuware (formerly from Xact Consulting). "The unified tool will leverage the best from both products and fundamentally change how customers create, execute and automate unit and integration tests for mainframe applications."

"The XaTester unit testing software has proven its value. I am pleased that Compuware will work to blend its capabilities with Topaz for Total Test as it will benefit all mainframe customers," said Elvin Høyer, CEO at Xact Consulting.   

"The new rules of the digital economy are putting pressure on our customers to achieve the utmost speed with the utmost quality," said Luke Tuddenham, Vice President at CPT, a global IT consulting services firm with a significant testing practice. "With today's announcements, Compuware has again demonstrated its leadership in innovative automated testing technologies for the mainframe that will help us help our clients to achieve this critical goal."

Compuware Topaz, a comprehensive suite of solutions, provides DevOps professionals at all skill levels with a visually intuitive environment where they can effectively understand and work on any mainframe application-regardless of age, complexity or lack of documentation. This simplified, streamlined approach is especially important as responsibility for applications running on the platform shifts from IT professionals with decades of mainframe-specific experience to a new generation of DevOps artisans who are more familiar with mainstream technologies such as Java and C++.

"REST and SOAP APIs provide the backbone of today's business-critical applications, especially when these services are used to access the power of the mainframe." said Parasoft VP of Products, Mark Lambert. "Test automation at the API layer is essential to delivering high quality at the speed of Agile and the Parasoft SOAtest plugin for Topaz brings API test automation directly to the mainframe developer, helping ensure the delivery of reliable, scalable and secure services."

Today's announcement comes during the 15th consecutive quarter that Compuware has delivered significant innovations that help large enterprises mainstream the mainframe, so they can better leverage the platform's unmatched performance, scalability, reliability, efficiency and security.

"Large enterprises increasingly recognize that digital innovation in the cloud must be paired with digital innovation on the mainframe," said Chris O'Malley, CEO of Compuware. "Compuware's passion and support for this mainframe-based digital innovation is unmatched-as we have once again demonstrated with this latest round of aggressive deliverables that enable Agile and DevOps best practices on the platform."

Compuware Corporation
Compuware empowers the world's largest companies to excel in the digital economy by fully leveraging their high-value mainframe investments. We do this by delivering highly innovative solutions that uniquely enable IT professionals with mainstream skills to manage mainframe applications, data, and platform operations. Learn more at compuware.com.

Follow us on:

Press Contact
Kristina LeBlanc, The Medialink Group, kristinawleblanc@gmail.com, (508) 930-5636
Mary McCarthy, Public Relations Manager, Compuware, mary.mccarthy@compuware.com, (313) 227-7088

For Sales and Marketing Information
Compuware Corporation, One Campus Martius, Detroit MI 48226, 800-266-7892, www.compuware.com.

Copyright © 2018, Compuware Corporation. All rights reserved. The Compuware products and services listed within this release are trademarks or registered trademarks of Compuware Corporation.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Compuware Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum